STOCK TITAN
  1. Home
  2. Sec-filings
  3. GPCR
  4. [Form 4] Structure Therapeutics Inc. American Insider Trading Activity

Structure Therapeutics (GPCR) Reports Director Option Grant in Form 4

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Structure Therapeutics Inc. (GPCR) – Form 4 insider filing

Director Eric Dobmeier reported the grant of 51,804 share options on 23 June 2025. The options carry an exercise price of $7.37 per ordinary share, equal to the fair-market value on the grant date. Vesting occurs in equal monthly instalments over twelve months beginning 23 June 2025; any unvested portion will become fully vested immediately prior to the company’s 2026 annual shareholder meeting. The options expire on 22 June 2035.

Following this grant, Mr. Dobmeier beneficially owns 51,804 derivative securities and no changes to his non-derivative share holdings were disclosed. Ownership is reported as direct. Each American Depositary Share represents three ordinary shares, but the filing reports the transaction in ordinary-share terms.

No open-market purchases, sales, or other equity transactions were reported. The filing therefore represents a routine board compensation event rather than a market transaction and is unlikely to have a material impact on near-term share price.

Positive

  • None.

Negative

  • None.

Insights

TL;DR – Routine option grant to GPCR director; no cash transaction, minimal immediate share-price impact.

The Form 4 shows a standard equity incentive: 51,804 options at $7.37, vesting over one year, expiring in 2035. The strike equals fair value, so the grant is non-dilutive today and aligns the director’s incentives with long-term performance. There is no indication of open-market buying or selling, so the transaction does not signal management’s view of the current valuation. Given GPCR’s ~125 m fully diluted ordinary shares, the potential dilution from this grant is immaterial (<0.05%). Investors should view the filing as customary governance housekeeping rather than a catalyst.

Insider DOBMEIER ERIC
Role Director
Type Security Shares Price Value
Grant/Award Share Option (right to buy) 51,804 $0.00 --
Holdings After Transaction: Share Option (right to buy) — 51,804 shares (Direct)
Footnotes (1)
  1. The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs"). The shares vest in equal monthly installments over the 12 months following June 23, 2025, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2026 annual shareholder meeting, The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
DOBMEIER ERIC
(Last) (First) (Middle)
C/O STRUCTURE THERAPEUTICS INC.
601 GATEWAY BLVD., SUITE 900
(Street)
SOUTH SAN FRANCISCO CA 94080
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Structure Therapeutics Inc. [ GPCR ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/23/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Share Option (right to buy) $7.37(1) 06/23/2025 A 51,804 (2) 06/22/2035 Ordinary Shares 51,804(3) $0 51,804 D
Explanation of Responses:
1. The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs").
2. The shares vest in equal monthly installments over the 12 months following June 23, 2025, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2026 annual shareholder meeting,
3. The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer.
/s/ Jun Yoon, Attorney-in-Fact 06/25/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

How many options did GPCR director Eric Dobmeier receive?

51,804 share options were granted on 23 June 2025.

What is the exercise price of the newly granted GPCR options?

The options are exercisable at $7.37 per ordinary share.

When do the GPCR options granted to Eric Dobmeier vest?

They vest in equal monthly instalments over 12 months after 23 June 2025, and will be fully vested before the 2026 annual meeting.

What is the expiration date of the options reported in the Form 4?

The options expire on 22 June 2035.

Do the reported options affect American Depositary Shares (ADSs)?

Yes. Each ADS represents three ordinary shares; the filing reports ordinary-share equivalents.